Compare · BIIB vs INAB
BIIB vs INAB
Side-by-side comparison of Biogen Inc. (BIIB) and IN8bio Inc. (INAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and INAB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $37.20B, about 4197.2x INAB ($8.9M).
- BIIB has been more active in the news (12 items in the past 4 weeks vs 5 for INAB).
- BIIB has more recent analyst coverage (25 ratings vs 5 for INAB).
- Company
- Biogen Inc.
- IN8bio Inc.
- Price
- -
- -
- Market cap
- $37.20B
- $8.9M
- 1M return
- +7.51%
- -
- 1Y return
- +52.33%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 12
- 5
- Recent ratings
- 25
- 5
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
IN8bio Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Latest BIIB
- New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
- FDA Approval for ZURZUVAE issued to BIOGEN
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
- SEC Form SCHEDULE 13G filed by Biogen Inc.
- ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
- Stoke Therapeutics to Present at Upcoming Investor Conferences in November
- Head of Research Grogan Jane converted options into 695 shares and covered exercise/tax liability with 345 shares, increasing direct ownership by 9% to 4,408 units (SEC Form 4)
- Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
- Biogen upgraded by Argus with a new price target
- Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Latest INAB
- IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
- IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 10-Q filed by IN8bio Inc.
- IN8bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- IN8bio to Present at Sidoti Small-Cap Virtual Conference
- IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
- IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
- Amendment: SEC Form SCHEDULE 13G/A filed by IN8bio Inc.